Chief Business Officer and member of the Executive Committee at Cellectis. Cellectis is a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies. Arthur is also a Board member at Primera Therapeutics, a biotechnology company developing patient-centric gene therapies targeting the root cause of mitochondrial disorders, and a Board Advisor of the US non-profit Life Science Cares. Arthur began his career at the European Commission’s Directorate-General for Competition controlling global pharmaceutical mergers. He later became Head of the Hospital Financing unit at the French Ministry of Health, where he led a team responsible for the national hospital budget. Arthur graduated from the École normale supérieure and Cambridge University, and holds a diploma in Immunotherapy from the University of Paris. Arthur is also a member of the French Corps des mines.
For a reasonably open world
